18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer

Cancer

Volumn 115, Issue 21, 2009, Pages 5038-5047

  Alberini, Jean Louis ^a,c   Lerebours, Florence ^a   Wartski, Myriam ^a   Fourme, Emmanuelle ^a   Le Stanc, Elise ^b   Gontier, E ^a   Madar, O ^a   Cherel, P ^a   Pecking, A P ^a  

^a Cancer Research Center Rene Huguenin   (France)

^b FOCH HOSPITAL   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Breast cancer; Fluorodeoxyglucose; Metastases; PET CT; Prognosis; Staging

Indexed keywords

ANTHRACYCLINE; FLUORODEOXYGLUCOSE F 18; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; AXILLA; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE SEVERITY; DISTANT METASTASIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HUMAN; INFLAMMATORY BREAST CANCER; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; MASTITIS; PATHOLOGY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SURGICAL TECHNIQUE; TUMOR LOCALIZATION;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFLAMMATION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 70350501252     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24534     Document Type: Article

References (28)

1. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol. 1992;10:1014-1024.
2. Lerebours F, Bieche I, Lidereau R. Update on inflammatory breast cancer. Breast Cancer Res. 2005;7:52-58.
3. Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer. 1998;82: 2366-2372.
4. Hance K, Anderson W, Devesa S, Young H, Levine P. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97:966-975. (Pubitemid 41430562)
5. Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist. 2003;8:141-148. (Pubitemid 36428280)
6. Singletary S, Allred C, Ashley P, et al. Revision of the American Joint Committee on cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628-3636. (Pubitemid 34983222)
7. Sataloff D, Mason B, Prestipino A, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Sur. 1995;180:297-306.
8. Chow CK. Imaging in inflammatory breast carcinoma. Breast Dis. 2005;22:45-54.
9. Yang WT, Le-Petross HT, Macapinlac H, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2007;109: 417-426.
10. Bonnier P, Charpin C, Lejeune C, et al. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer. 1995;62:382-385.
11. Amparo RS, Angel CD, Ana LH, et al. Inflammatory breast carcinoma: pathological or clinical entity? Breast Cancer Res Treat. 2000;64:269-273.
12. Bakheet SM, Powe J, Kandil A, Ezzat A, Rostom A, Amartey J. F-18 FDG uptake in breast infection and inflammation. Clin Nucl Med. 2000;25:100-103. (Pubitemid 30068866)
13. Schirrmeister H, Kuhn T, Guhlman H, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med. 2001;28:351-358. (Pubitemid 32247146)
14. Eubank W, Mankoff D, Takasugi J, et al. 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol. 2001;19:3516-3523. (Pubitemid 32730089)
15. Bellon JR, Livingston RB, Eubank WB, et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol. 2004;27:407-410. (Pubitemid 39045254)
16. Klaeser B, Wiederkehr O, Koeberle D, Mueller A, Bubeck B, Thuerlimann B. Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer. Ann Oncol. 2007;18:1329-1334. (Pubitemid 47305005)
17. Port E, Yeung H, Gonen M, et al. 18-2-Fluoro-2-Deoxy- D-glucose Positron Emission Tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma. Ann Surg Oncol. 2006;13:677-684.
18. Baslaim MM, Bakheet SM, Bakheet R, Ezzat A, El-Foudeh M, Tulbah A. 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer. World J Surg. 2003;27:1099-1104. (Pubitemid 37259988)
19. Mahner S, Schirrmacher S, Brenner W, et al. Comparison between positron emission tomography using 2-[fluorine- 18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol. 2008;19:1249-1254. (Pubitemid 351911953)
20. Groheux D, Moretti J, Baillet G, et al. Effect of F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys. 2008;71:695-704.
21. Fuster D, Duch J, Paredes P, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;10:4746-4751.
22. Singletary SE, Cristofanilli M. Defining the clinical diagnosis of inflammatory breast cancer. Semin Oncol. 2008;35:7-10. (Pubitemid 351282390)
23. Giordano S, Hortobagyi G. Inflammatory breast cancer. Clinical progress and the main problems that must be addressed. Breast Cancer Res. 2003;5:284-288.
24. Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F] -D-glucose. Cancer. 1998;82:2227-2234.
25. Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S. Preoperative evaluation of prognosis in breast cancer patients by [F]2-Deoxy-2-fluoro-D- glucose-positron emission tomography. J Cancer Res Clin Oncol. 2004;130: 273-278. (Pubitemid 38680268)
26. Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med. 1998;25:1429-1434. (Pubitemid 28464119)
27. Wu M, Merajver SD. Molecular biology of inflammatory breast cancer: applications to diagnosis, prognosis, and therapy. Breast Dis. 2005;22:25-34. (Pubitemid 44308939)
28. Le-Petross C, Bidaut L, Yang W. Evolving role of imaging modalities in inflammatory breast cancer. Semin Oncol. 2008;35:51-63. (Pubitemid 351282396)